The White House is putting a new price tag on President Donald Trump's prescription drug campaign, saying voluntary agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.
The estimate comes from White House economists analyzing Trump's "most favored nation" drug-pricing push, a policy designed to bring U.S. prices closer to those paid in other wealthy countries. According to The Associated Press, the White House says agreements with 17 pharmaceutical companies could generate broad economic savings by lowering prescription drug costs, reducing public health spending, and easing financial pressure on households, employers, and government programs.
